IGF2 and pulmonary arterial hypertension: Studies have suggested that IGF-2 signaling may contribute to endothelial dysfunction and smooth muscle proliferation, both of which are critical pathological features of PAH (Chisalita et al., 2009; Jang et al., 2022; Tan et al., 2021).